BioMarin Pharmaceutical Inc. (BMRN)

Check out top investors' recommendation for BMRN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company’s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Cory Kasimov JPMorgan Buy   Jan 08, '18       Jan 08, '19  N/A 
Jami Rubin Goldman Sachs Buy   Dec 15, '17     131.00  Dec 15, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Dec 14, '17       Dec 14, '18  N/A 
Edward Nash Cowen And Company Buy   Dec 11, '17     130.00  Dec 11, '18  N/A 
Cory Kasimov JPMorgan Buy   Nov 27, '17     131.00  Nov 27, '18  N/A 
Cory Kasimov JPMorgan Buy   Oct 27, '17     130.00  Oct 27, '18  N/A 
Ian Somaiya Piper Jaffray Buy   Oct 27, '17     119.00  Oct 27, '18  N/A 
Edward Nash Cowen And Company Buy   Oct 19, '17     115.00  Oct 19, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Oct 19, '17     124.00  Oct 19, '18  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Oct 19, '17     142.00  Oct 19, '18  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Oct 18, '17     107.00  Oct 18, '18  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Oct 18, '17     113.00  Oct 18, '18  N/A 
Salveen Richter Canaccord Genuity Buy   Oct 06, '17     124.00  Oct 06, '18  N/A 
Brian Skorney Brean Murray, Carret & Co. Buy   Oct 03, '17     115.00  Oct 03, '18  N/A 
Michael Yee RBC Capital Markets Buy   Sep 25, '17     116.00  Sep 25, '18  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Sep 13, '17     113.00  Sep 13, '18  N/A 
Robyn Karnauskas Deutsche Bank Securities Buy   Aug 30, '17     98.00  Aug 30, '18  N/A 
Eun Yang Jefferies & Co. Buy   Aug 24, '17     116.00  Aug 24, '18  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Aug 03, '17     107.00  Aug 03, '18  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Jul 18, '17       Jul 18, '18  N/A 
< previous123456